Top Health Tech Companies in Bengaluru (124)

Strong Revenue Growth: Company-reported results indicate 34% year-over-year software growth in 2024, alongside earlier periods of 100% YoY elluminate software growth in 2022 and 50% in 2021. These signals point to sustained momentum in the software business.

Market Expansion: The organization added 20 net-new clients in 2024 and more than 20 in 2025, with its footprint among top global pharma expanding from 16 to 18 of the world’s top 50 companies. This reflects a widening customer base across large enterprise accounts.

Investor Backing & Capital Strength: A September 2024 majority investment by GI Partners—described as a growth investment—with previous investor Summit Partners retaining a minority stake indicates strong institutional support. Subsequent expansion of the executive team aligns with funding to drive the next phase of growth.

Strong Hiring & Retention: Hiring and headcount are expanding, with disclosures of 15,000+ global employees, thousands of new hires, and third‑party estimates indicating continued workforce growth. Available evidence also points to active internal mobility and a recent increase in active job postings.

Market Expansion: Geographic and client footprints are broadening, with 40+ offices and 1,700+ customers across 170+ countries alongside concrete investments in new and expanded locations such as Hyderabad and Kingston. These moves indicate scaling delivery capacity in major capability centers and new regions.

Innovation-Driven Growth: The offering mix is shifting toward AI, data, technology, and platforms, including proprietary solutions and product capabilities. Strategic moves such as Salesforce-focused acquisitions and collaborations, plus a Tulip solution partnership, extend capabilities beyond traditional consulting.

Strong Revenue Growth: Optum’s consolidated revenue expanded from $253.0B in 2024 to $270.6B in 2025, indicating continued top-line growth. Multi‑year reporting also highlights ongoing increases at the consolidated level even as segment performance diverges.

Diversified Revenue Streams: Performance is spread across three businesses, with Optum Rx delivering substantial gains, Optum Insight growing modestly, and Optum Health contracting. This mix shows pharmacy and technology services helping sustain overall scale despite softness in care delivery.

Cost & Operational Efficiency: Operating performance improved in 2026 as Optum’s operating income rose year over year to about $4B in Q2 alongside reported gains in technology and clinical operations. UnitedHealth also raised its 2026 adjusted EPS outlook, signaling confidence in execution.

Strong Revenue Growth: Recent results indicate total revenue increased year over year in 2025 and continued to rise in the latest reported quarter. Guidance and quarterly updates point to ongoing top-line expansion even as mix shifts occur.

Resilient & Sustainable Growth: Underlying annual contract value expanded and accelerated in 2026, with management indicating continued growth despite the transition to hosted licensing. This suggests the core subscription base is strengthening even when reported revenue timing varies.

Diversified Revenue Streams: Growth is visible in both the software business and the milestone-driven drug discovery segment. The latter stepped up meaningfully in recent periods, complementing steady software momentum.

Strong Market Position & Advantage: Rankings on the 2026 Fortune 500 and Global 500 reflect industry-leading revenue scale. AM Best identifies the company as the largest public insurer in the U.S./Canada, with Optum Rx among the "Big 3" PBMs.

Diversified Revenue Streams: A vertically integrated model spans UnitedHealthcare and Optum (Health, Insight, Rx), combining insurance, care delivery, pharmacy benefits, and analytics. This breadth supports performance across funding cycles and care settings.

Strong Revenue Growth: Consolidated revenue rose to about $447.6 billion in 2025 from $400.3 billion in 2024, and 2026 has delivered consecutive quarters around $112 billion while full-year earnings guidance was raised.

Strong Market Position & Advantage: Industry and company materials indicate ResMed is the leading player in global sleep‑apnea devices and masks, supported by scale and a large connected ecosystem (AirView/myAir). Philips’ U.S. consent decree and extended remediation have provided a multi‑year window that reinforced ResMed’s relative momentum.

Strong Revenue Growth: Recent quarters show continued year‑over‑year revenue growth with margin expansion, driven by device demand and recurring masks/accessories. Management commentary and investor materials point to sustained momentum through FY2026 to date.

Diversified Revenue Streams: A large installed base of connected devices underpins recurring resupply revenue and remote monitoring workflows. Ownership of Brightree and MatrixCare adds out‑of‑hospital software that complements the core hardware franchise.

Strong Revenue Growth: Revenue increased substantially in 2024 to $6.06 billion, with quarterly results showing robust year-over-year gains. Membership on the platform also expanded meaningfully by year-end 2024, supporting the top line.

Strong Market Position & Advantage: The company operates one of the larger physician-enablement platforms focused on full-risk Medicare seniors, with a national footprint across 30+ communities and hundreds of thousands of covered lives. Its specialization in partnering with independent groups under global risk distinguishes it from broader, lighter-risk enablement peers.

Strategic Partnerships: Long-term arrangements with independent physician groups continued to expand with new marquee partners and entries into additional states. The partnership model provides aligned incentives and supports physician demand for enablement in value-based care.

Strong Market Position & Advantage: GE HealthCare is positioned as a top-tier global medical technology player with leadership across diagnostic imaging, ultrasound, and pharmaceutical diagnostics, supported by a very large installed base and operations in over 160 countries. Scale and portfolio breadth across major modalities and care settings are repeatedly presented as durable advantages that support recurring service, upgrades, and consumables/software revenue.

Innovation-Driven Growth: R&D investment exceeding $1B annually and an active pipeline of many products in imaging, digital health, and in vitro diagnostics indicate a sustained innovation engine. The emphasis on AI-enabled devices and new product introductions (e.g., photon-counting CT and other launches) is framed as a multi-year driver that should increase contribution to revenue over time.

Resilient & Sustainable Growth: Orders and backlog signals (book-to-bill above 1.0, growing orders, and a reported record backlog) suggest demand is keeping pace with shipments and provides forward visibility. Guidance for continued low-single-digit organic growth alongside expectations for EPS growth and meaningful free cash flow points to steady, defensible expansion rather than cyclical contraction.